See more : Oaktree Strategic Income Corporation (OCSI) Income Statement Analysis – Financial Results
Complete financial analysis of IN8bio, Inc. (INAB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of IN8bio, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- U.S. Energy Corp. (USEG) Income Statement Analysis – Financial Results
- Inception Growth Acquisition Limited (IGTAR) Income Statement Analysis – Financial Results
- Chambal Fertilisers and Chemicals Limited (CHAMBLFERT.BO) Income Statement Analysis – Financial Results
- KINS Technology Group Inc. (KINZW) Income Statement Analysis – Financial Results
- NoHo Partners Oyj (NOHO.HE) Income Statement Analysis – Financial Results
IN8bio, Inc. (INAB)
About IN8bio, Inc.
IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation. It also develops INB-400 and INB-300 that is in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 2.50M | 1.10M | 251.00K | 96.00K | 96.00K | 96.00K |
| Gross Profit | -2.50M | -1.10M | -251.00K | -96.00K | -96.00K | -96.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 16.83M | 14.06M | 7.35M | 5.38M | 2.36M | 581.00K |
| General & Administrative | 13.51M | 14.46M | 7.31M | 3.18M | 2.71M | 1.42M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 13.51M | 14.46M | 7.31M | 3.18M | 2.71M | 1.42M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -63.00K |
| Operating Expenses | 30.34M | 28.52M | 14.65M | 8.56M | 5.07M | 2.00M |
| Cost & Expenses | 30.34M | 28.52M | 14.65M | 8.56M | 5.07M | 2.00M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 14.00K |
| Depreciation & Amortization | 1.83M | 1.10M | 251.00K | 96.00K | 96.00K | 96.00K |
| EBITDA | -28.50M | -27.42M | -14.40M | -8.47M | -5.04M | -1.97M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -30.34M | -28.52M | -14.65M | -8.56M | -5.13M | -2.00M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 330.00K | 0.00 | 0.00 | 0.00 | 0.00 | -77.00K |
| Income Before Tax | -30.01M | -28.52M | -14.65M | -8.56M | -5.13M | -2.08M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -1.10M | 551.44K | -118.30K | -68.00K | -63.00K |
| Net Income | -30.01M | -27.42M | -14.65M | -8.56M | -5.13M | -2.08M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.00 | -1.31 | -0.78 | -0.44 | -0.27 | -0.34 |
| EPS Diluted | -1.00 | -1.31 | -0.78 | -0.44 | -0.27 | -0.34 |
| Weighted Avg Shares Out | 29.86M | 20.97M | 18.78M | 19.35M | 19.35M | 6.17M |
| Weighted Avg Shares Out (Dil) | 29.86M | 20.97M | 18.78M | 19.35M | 19.35M | 6.17M |
IN8bio to Present Positive Preclinical Data on Novel Gamma-Delta CAR Platform at AACR Annual Meeting 2023
NEW YORK, March 16, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies, has announced that preclinical data for its gamma-delta CAR-T technology, INB-300, will be presented at the...
IN8bio to Present at the Cowen 43rd Annual Healthcare Conference
NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies, today announced William Ho, CEO and co-founder, will present a company overview at the Cowen 43rd...
IN8bio to Present at the H.C. Wainwright Cell Therapy Virtual Conference
NEW YORK, Feb. 21, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies, today announced William Ho, CEO and co-founder, will present a fireside chat at the H.C. Wainwright...
IN8bio to Present at the B. Riley Securities' 3rd Annual Virtual Oncology Conference
NEW YORK, Jan. 17, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies, today announced William Ho, CEO and co-founder, will present a company overview at the B. Riley...
IN8bio to Present at Biotech Showcase 2023 in San Francisco
NEW YORK, Jan. 03, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies, today announced William Ho, CEO and co-founder, will present at Biotech Showcase 2023 on Monday, January...
IN8bio to Present Positive Early Data from Ongoing Phase 1 Study of INB-100 at the 64th American Society of Hematology Annual Meeting
NEW YORK, Nov. 03, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies that utilize its DeltEx platform, today announced positive early data from the ongoing Phase 1 trial...
IN8bio to Present at November Investor Conferences
NEW YORK, Nov. 01, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies that utilize its DeltEx platform, today announced William Ho, CEO and co-founder, will be presenting at...
IN8bio to Present at Cantor Oncology & HemOnc Conference
NEW YORK, Sept. 27, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies that utilize its DeltEx platform, today announced that William Ho, IN8bio's Chief Executive Officer, will be...
IN8bio to Present at H.C. Wainwright 24th Annual Global Investment Conference
NEW YORK, Sept. 13, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies that utilize its DeltEx platform, today announced William Ho, IN8bio's Chief Executive Officer will be participating...
11 Insiders Tip More Capital into IN8BIO and Broker HC Wainwright Initiates With Bullish $14 Target
Clinical stage biopharmaceutical company IN8bio Inc (US:INAB) topped the Fintel Significant Insider Buying Activity screen this week with 11 insiders buying over the last 90 days.
Source: https://incomestatements.info
Category: Stock Reports